Aditya Birla Sun Life Pharma and Healthcare Fund
Aditya Birla Sun Life Pharma and Healthcare Fund portfolio holdings, Oct 2026: 40 stocks, ₹1,082 cr in listed equity, from Aditya Birla Sun Life Mutual Fund's monthly disclosure; changes by share count against Sep 2026.
Fund managers: Dhaval Shah (Primary, since 11 Jul 2019)
Benchmark: BSE Healthcare TRI · Riskometer: Very High · SEBI category, as filed: Equity Scheme - Thematic · Allotted 11 Jul 2019
Source: AMFI scheme summary document
Aditya Birla Sun Life Pharma and Healthcare Fund - Direct Plan - GROWTH
Source: AMFI
The scheme's yearly running cost as a % of its assets, taken out of the NAV a little each day. A regular plan costs more: it pays a distributor's commission.
Category median: direct 1.23 %, regular 2.40 % (174 schemes) · Regular costs ₹1,230 more a year per ₹1 lakh
Of this, the base expense ratio, the part SEBI caps: direct 0.81 %, regular 1.88 %. The rest is brokerage, transaction costs and statutory levies such as GST and STT, as AMFI's file lists them.
A year, as of 19 Nov 2026. Source: AMFI · Glossary: TER
40 stocks, Oct 2026.
As the AMC's file prints % of NAV. The top 10 stocks together: 54.6%.
This month: Oct 2026
compared with Sep 2026 · by share countMoves, Oct 2026
How many stocks the scheme bought into, added to, cut or sold out of this month, by share count, so a price move alone never counts.
- New2
- Added7
- Trimmed1
- Exited1
Asset mix, Oct 2026
How much of the fund sits in listed shares; the rest is foreign shares, debt, money market, cash and other assets.
- Listed equity99.4%
- Rest, not itemised0.6%
Rest = foreign shares, debt, money market, cash, REIT/InvIT units and other assets.
Sectors and top 10, Oct 2026
Sector mix, Oct 2026
How the scheme's equity is spread across sectors at month end.
- 98.7%
- 0.7%
- 0.6%
AMFI's 22 sectors; one sector per stock, from the fund houses' industry labels.
Large, mid and small cap, Oct 2026
How the scheme's equity splits across large, mid and small companies, on AMFI's list.
- Small Cap34.7%
- Large Cap33.4%
- Mid Cap30.9%
- Not in AMFI's list1.0%
AMFI's list of Jun 2026.
Top 10 holdings
Its ten largest stocks, each as a share of the fund.
- 8.83%
- 8.35%
- 7.10%
- 6.60%
- 4.54%
- 4.50%
- 4.17%
- 3.90%
- 3.56%
- 3.06%
As the AMC's file prints % of NAV.
Sector weight change
Each sector's share of the fund now less a month before. It moves with prices as well as trades.
- +0.2 pts
- −0.1 pts
Largest moves first, up to 10.
| Stock | Change | Shares before | Shares now | Difference | Change % | Value of change | Value now |
|---|---|---|---|---|---|---|---|
| ERIS | New | — | 1.50 lakh | +1.50 lakh | — | +₹17.3 cr | ₹17.3 cr |
| ONESOURCE | New | — | 60,000 | +60,000 | — | +₹9.4 cr | ₹9.4 cr |
| CIPLA | Added | 5.10 lakh | 5.60 lakh | +50,000 | +9.8% | +₹6.9 cr | ₹77.3 cr |
| LALPATHLAB | Added | 1.90 lakh | 2.23 lakh | +32,456 | +17.1% | +₹6.2 cr | ₹42.4 cr |
| DRREDDY | Added | 98,975 | 1.49 lakh | +50,000 | +50.5% | +₹6.8 cr | ₹20.1 cr |
| BIOCON | Added | 4.22 lakh | 5.52 lakh | +1.30 lakh | +30.8% | +₹4.6 cr | ₹19.4 cr |
| METROPOLIS | Added | 2.94 lakh | 3.07 lakh | +12,912 | +4.4% | +₹0.70 cr | ₹16.7 cr |
| PPLPHARMA | Added | 6.38 lakh | 6.98 lakh | +60,000 | +9.4% | +₹1.4 cr | ₹16.7 cr |
| NATCOPHARM | Added | 1.20 lakh | 1.31 lakh | +11,428 | +9.5% | +₹0.89 cr | ₹10.3 cr |
| GLAXO | Trimmed | 32,390 | 22,908 | −9,482 | −29.3% | −₹2.4 cr | ₹5.7 cr |
| SHILPAMED | Exited | 1.47 lakh | — | −1.47 lakh | — | −₹15.4 cr | ₹15.4 cr |
Value of change = the difference in shares × this month's price in the AMC's file. Value now = the whole holding's market value in that file (an exit: last month's).
Show all 40 stocksShow the first 15
Equity rows as disclosed, Oct 2026. Source: Aditya Birla Sun Life Mutual Fund monthly portfolio. Report a wrong number
Large, mid and small caps, % of net assets, last 12 months
AMFI list in force each month
| Month | Large | Mid | Small | Not in AMFI's list | AMFI list |
|---|---|---|---|---|---|
| Oct 2026 | 33.2% | 30.7% | 34.5% | 1.0% | Jun 2026 |
| Sep 2026 | 32.9% | 30.6% | 33.3% | 1.1% | Jun 2026 |
| Aug 2026 | 33.0% | 30.4% | 31.8% | 1.1% | Jun 2026 |
| Jul 2026 | 33.3% | 31.1% | 32.3% | 0.9% | Jun 2026 |
| Jun 2026 | 30.8% | 26.1% | 40.9% | 0.0% | Dec 2025 |
| May 2026 | 31.4% | 26.5% | 38.9% | 0.0% | Dec 2025 |
| Apr 2026 | 32.5% | 28.0% | 38.1% | 0.0% | Dec 2025 |
| Mar 2026 | 33.1% | 28.3% | 36.3% | 0.0% | Dec 2025 |
| Feb 2026 | 34.2% | 27.7% | 36.5% | 0.0% | Dec 2025 |
| Jan 2026 | 33.1% | 28.1% | 36.8% | 0.0% | Dec 2025 |
| Dec 2025 | 42.3% | 25.1% | 29.4% | 1.9% | Jun 2025 |
| Nov 2025 | 42.8% | 25.3% | 29.6% | 0.0% | Jun 2025 |
Equity holdings' % of net assets each month, by AMFI's cap list in force that month.
Portfolio turnover, from holdings
equity only · month-end snapshots
| Month | Bought | Sold | Turnover |
|---|---|---|---|
| Oct 2026 | ₹54.2 cr | ₹16.4 cr | 1.5% |
| Sep 2026 | ₹32.2 cr | ₹0.00 cr | 0.0% |
| Aug 2026 | ₹20.2 cr | ₹27.7 cr | 1.9% |
| Jul 2026 | ₹94.6 cr | ₹73.5 cr | 7.2% |
| Jun 2026 | ₹38.2 cr | ₹22.2 cr | 2.3% |
| May 2026 | ₹5.4 cr | ₹15.1 cr | 0.6% |
| Apr 2026 | ₹15.3 cr | ₹7.9 cr | 0.9% |
| Mar 2026 | ₹25.9 cr | ₹0.00 cr | 0.0% |
| Feb 2026 | ₹4.2 cr | ₹0.00 cr | 0.0% |
| Jan 2026 | ₹8.0 cr | ₹14.6 cr | 1.0% |
| Dec 2025 | ₹31.0 cr | ₹18.6 cr | 2.2% |
| Nov 2025 | ₹20.4 cr | ₹14.7 cr | 1.8% |
The lower of bought and sold over the average equity value, from month-end holdings; it can differ from the fund house's own figure.
| Period | Direct plan | Regular plan | Benchmark, as published by AMFI BSE Healthcare TRI |
|---|---|---|---|
| 1 year | +19.38 % | +17.81 % | +19.11 % |
| 3 years | +19.95 % | +18.37 % | +22.11 % |
| 5 years | +15.94 % | +14.35 % | +16.69 % |
| Since launch | +21.14 % | +19.33 % | +22.13 % |
Past performance may not be sustained in future.
As AMFI's fund performance report prints them for "Aditya Birla Sun Life Pharma & Healthcare Fund"; this site computes no benchmark figure of its own.
How it is computed: NAV to NAV
Aditya Birla Sun Life Pharma and Healthcare Fund - Direct Plan - GROWTH: these run to the newest NAV stored (20 Nov 2026) and are computed here from AMFI's NAV files; AMFI's figures above run to 19 Nov 2026, so the two differ by the days in between.
| Period | Return | From | To |
|---|---|---|---|
| 1 year | +21.04 % in total | 20 Nov 2025 · NAV ₹34.3200 | 20 Nov 2026 · NAV ₹41.5400 |
| 3 years | +20.35 % a year, compounded | 20 Nov 2023 · NAV ₹23.8200 | 20 Nov 2026 · NAV ₹41.5400 |
| 5 years | +16.19 % a year, compounded | 18 Nov 2021 · NAV ₹19.5900 | 20 Nov 2026 · NAV ₹41.5400 |
| Since first NAV | +21.24 % a year, compounded | 11 Jul 2019 · NAV ₹10.0500 | 20 Nov 2026 · NAV ₹41.5400 |
Source: AMFI NAV files (plan code 147409). How to read Report a wrong number
IDCW (dividend) history
0 declarations · as of 2 Nov 2026 · Source: AMFI
IDCW (formerly "dividend") declared per unit of each IDCW plan, as AMFI lists it.
Rolling returns, Aditya Birla Sun Life Pharma and Healthcare Fund - Direct Plan - GROWTH
weekly NAVs · Source: AMFI
| Window | Lowest | Median | Highest | Windows above zero |
|---|---|---|---|---|
| 1 year in total | −14.11 % 9 Sep 2021 to 16 Sep 2022 | +18.53 % 24 Jun 2022 to 30 Jun 2023 | +70.82 % 27 Mar 2020 to 1 Apr 2021 | 80 % of 330 windows ending 17 Jul 2020 to 20 Nov 2026 |
| 3 years a year, compounded | +11.32 % 18 Sep 2020 to 22 Sep 2023 | +19.70 % 13 Dec 2019 to 16 Dec 2022 | +27.35 % 19 May 2023 to 22 May 2026 | 100 % of 228 windows ending 15 Jul 2022 to 20 Nov 2026 |
| 5 years a year, compounded | +12.89 % 14 Oct 2021 to 16 Oct 2026 | +17.55 % 23 Oct 2020 to 24 Oct 2025 | +28.62 % 11 Oct 2019 to 11 Oct 2024 | 100 % of 124 windows ending 12 Jul 2024 to 20 Nov 2026 |
Past performance may not be sustained in future.
Every 1-, 3- and 5-year window ending on a week's last NAV, lowest, middle and highest.
Standard deviation of weekly NAV changes × √52. 24 Nov 2023 to 20 Nov 2026, 156 weekly changes.
Source: AMFI
High 3 Sep 2021, low 17 Jun 2022; back at the high 21 Jul 2023.
Weekly NAVs since 12 Jul 2019. Measured on each week's last NAV, so a fall within a week can be deeper than shown.
Source: AMFI
Past performance may not be sustained in future.
Next to its category: Sectoral or thematic
weekly NAVs · Source: AMFI
| Rolling window | Lower quarter | Upper quarter | Above 6 % | Above 9 % | Above 12 % | Above the category average |
|---|---|---|---|---|---|---|
| 1 year | +4.3 % | +46.3 % | 73.3 % | 70.3 % | 64.8 % | 52.4 % of 330 windows |
| 3 years | +16.5 % | +22.6 % | 100.0 % | 100.0 % | 99.6 % | 48.2 % of 228 windows |
| 5 years | +14.9 % | +23.7 % | 100.0 % | 100.0 % | 100.0 % | 42.7 % of 124 windows |
Same windows as the rolling returns above. A quarter of the windows returned less than the lower quarter, and a quarter more than the upper. "Above" columns give the share of windows. The category average is the average for windows ending the same week.
Market phases
| Phase | Dates | This scheme | Category average |
|---|---|---|---|
| Rise from the COVID low | 27 Mar 2020 to 27 Sep 2024 a year, compounded | +32.9 % | +37.3 % 70 schemes |
| Foreign selling, 2024–25 | 27 Sep 2024 to 28 Feb 2025 in total | −15.3 % | −19.1 % 148 schemes |
| Since March 2025 | 28 Feb 2025 to 20 Nov 2026 a year, compounded | +20.9 % | +15.6 % 165 schemes |
The phases are the site's own split of the market since 2015, measured from month end to month end.
From each quarter end to the newest NAV
| From | Dates | This scheme | Category average |
|---|---|---|---|
| From Jun 2026 | 25 Jun 2026 to 20 Nov 2026 in total | +9.0 % | +4.6 % 195 schemes |
| From Mar 2026 | 27 Mar 2026 to 20 Nov 2026 in total | +22.7 % | +18.1 % 195 schemes |
| From Dec 2025 | 26 Dec 2025 to 20 Nov 2026 in total | +22.4 % | +6.8 % 188 schemes |
| From Sep 2025 | 26 Sep 2025 to 20 Nov 2026 a year, compounded | +20.8 % | +8.9 % 182 schemes |
| From Jun 2025 | 27 Jun 2025 to 20 Nov 2026 a year, compounded | +16.6 % | +6.0 % 173 schemes |
| From Mar 2025 | 28 Mar 2025 to 20 Nov 2026 a year, compounded | +16.8 % | +11.9 % 169 schemes |
| From Dec 2024 | 27 Dec 2024 to 20 Nov 2026 a year, compounded | +10.2 % | +5.8 % 159 schemes |
| From Sep 2024 | 27 Sep 2024 to 20 Nov 2026 a year, compounded | +7.8 % | +1.6 % 148 schemes |
| From Jun 2024 | 28 Jun 2024 to 20 Nov 2026 a year, compounded | +15.7 % | +5.4 % 139 schemes |
| From Mar 2024 | 28 Mar 2024 to 20 Nov 2026 a year, compounded | +15.2 % | +9.9 % 133 schemes |
| From Dec 2023 | 29 Dec 2023 to 20 Nov 2026 a year, compounded | +18.5 % | +11.6 % 127 schemes |
| From Sep 2023 | 29 Sep 2023 to 20 Nov 2026 a year, compounded | +20.9 % | +14.6 % 118 schemes |
Root mean square of the weekly falls × √52 (rising weeks count as zero).
Its average change in the 92 weeks the category average rose, as a share of the category's.
The same for the 64 weeks the category average fell.
Past performance may not be sustained in future.
Category average = the plain average for the other schemes in the same AMFI category with the same figure (direct growth plans, each week's last NAV). It is not an index, and the scheme's place among them is not shown. Peers are today's schemes in today's category, so a scheme that has closed is not in the average, and SEBI re-sorted the categories in 2018.
Highest and lowest of 248 daily NAVs, 20 Nov 2025 to 20 Nov 2026, Aditya Birla Sun Life Pharma and Healthcare Fund - Direct Plan - GROWTH.
Source: AMFI
Calendar-year returns, Aditya Birla Sun Life Pharma and Healthcare Fund - Direct Plan - GROWTH
NAV to NAV · Source: AMFI
| Year | Return | From | To |
|---|---|---|---|
| 2025 | −3.09 % | 31 Dec 2024 · NAV ₹34.9600 | 31 Dec 2025 · NAV ₹33.8800 |
| 2024 | +37.69 % | 29 Dec 2023 · NAV ₹25.3900 | 31 Dec 2024 · NAV ₹34.9600 |
| 2023 | +39.58 % | 30 Dec 2022 · NAV ₹18.1900 | 29 Dec 2023 · NAV ₹25.3900 |
| 2022 | −11.31 % | 31 Dec 2021 · NAV ₹20.5100 | 30 Dec 2022 · NAV ₹18.1900 |
| 2021 | +21.36 % | 31 Dec 2020 · NAV ₹16.9000 | 31 Dec 2021 · NAV ₹20.5100 |
| 2020 | +56.63 % | 31 Dec 2019 · NAV ₹10.7900 | 31 Dec 2020 · NAV ₹16.9000 |
Past performance may not be sustained in future.
Change in the plan's NAV over each calendar year, last NAV to last NAV. Source: AMFI NAV files. How to read
Monthly SIP of ₹10,000, Aditya Birla Sun Life Pharma and Healthcare Fund - Direct Plan - GROWTH
XIRR · Source: AMFI
| Period | Instalments | Paid in | Value | XIRR, a year |
|---|---|---|---|---|
| 1 year 1 Dec 2025 to 2 Nov 2026 | 12 | ₹1,20,000 | ₹1,36,921 20 Nov 2026 · NAV ₹41.5400 | +28.83 % |
Past performance may not be sustained in future.
₹10,000 on the first NAV of each month, valued at the newest NAV; no stamp duty, exit load or tax taken off.
Embed this card
Copy this into any web page. The image carries its source, date and a link back; it is redrawn each night.
- Nippon India Pharma Fund65.8% overlap29 in common
- Mirae Asset Healthcare Fund56.1% overlap19 in common
- UTI - Healthcare Fund52.2% overlap29 in common
- Baroda BNP Paribas Health and Wellness Fund51.7% overlap19 in common
- PGIM India Healthcare Fund50.0% overlap17 in common
Overlap is the sum, over stocks both hold, of the smaller of the two weights. A measured likeness, not a suggestion to switch.
- Aditya Birla Sun Life Pharma and Healthcare Fund vs Nippon India Pharma Fund65.8% overlap29 in common
- 8 Nov 2026 · TER change: Aditya Birla Sun Life Pharma and Healthcare Fund: AMFI TER file of 8 Nov 2026: regular plan 2.27% (was 2.28%); previous file 5 Nov 2026
- 5 Nov 2026 · TER change: Aditya Birla Sun Life Pharma and Healthcare Fund: AMFI TER file of 5 Nov 2026: direct plan 1.04% (was 1.05%); previous file 4 Nov 2026
- 4 Nov 2026 · TER change: Aditya Birla Sun Life Pharma and Healthcare Fund: AMFI TER file of 4 Nov 2026: regular plan 2.28% (was 2.29%); previous file 3 Nov 2026
- 31 Oct 2026 · TER change: Aditya Birla Sun Life Pharma and Healthcare Fund: AMFI TER file of 31 Oct 2026: direct plan 1.05% (was 1.06%); previous file 29 Oct 2026
- 29 Oct 2026 · TER change: Aditya Birla Sun Life Pharma and Healthcare Fund: AMFI TER file of 29 Oct 2026: direct plan 1.06% (was 1.07%); previous file 28 Oct 2026
From AMFI's own files (scheme summary documents, NAV history, TER), as they stood on the day shown.
Questions about Aditya Birla Sun Life Pharma and Healthcare Fund
from the figures on this pageWhat are the top holdings of Aditya Birla Sun Life Pharma and Healthcare Fund?
At Oct 2026 end, Aditya Birla Sun Life Pharma and Healthcare Fund held 40 stocks (99.4% of the fund in equity). Largest: Torrent Pharmaceuticals 8.83%, Sun Pharmaceutical Industries 8.35%, Cipla 7.10%, Apollo Hospitals Enterprise 6.60%, Sai Life Sciences 4.54%; the top 10 make up 54.6%. Funds holding Torrent Pharmaceuticals · Funds holding Sun Pharmaceutical Industries · Funds holding Cipla
What portfolio changes did Aditya Birla Sun Life Pharma and Healthcare Fund make in Oct 2026?
Compared with Sep 2026, by share count: 2 new, 7 added, 1 trimmed, 1 exited. Largest by value: Eris Lifesciences (new), Onesource Specialty Pharma (new), Cipla (added), Dr. Lal Path Labs (added).
Who manages Aditya Birla Sun Life Pharma and Healthcare Fund?
AMFI's scheme summary document names Dhaval Shah for Aditya Birla Sun Life Pharma and Healthcare Fund (Aditya Birla Sun Life Mutual Fund). Dhaval Shah, fund manager portfolio
All schemes of Aditya Birla Sun Life Mutual Fund →
Mutual fund investments are subject to market risks; read all scheme related documents carefully.